[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
November 1987

Topical Minoxidil Therapy for Androgenetic AlopeciaA 30-Month Study

Author Affiliations

From the Department of Dermatology, Stanford (Calif) University School of Medicine. Dr Koperski is now with Scripps Clinic and Research Foundation, La Jolla, Calif.

Arch Dermatol. 1987;123(11):1483-1487. doi:10.1001/archderm.1987.01660350083018

• Seventy-two adult male patients were entered into a double-blind, placebo-controlled investigation using 2% to 3% topical minoxidil solution for androgenetic alopecia. Fifty-nine patients completed the initial 12 months, and continued to use 3% topical minoxidil solution in an open study design. Hair regrowth (as measured by hair counts and bald-area diameters) was noted in all treatment groups at four months, and appeared to peak at approximately 12 months. At 30 months, mean hair counts had decreased from the 12-month level, but remained elevated over baseline counts, while mean bald-area diameters returned to baseline. However, 70% of the patients who did continue to use the drug for 30 months had 50% or more hairs than when they originally started the drug therapy. A subset of patients appeared to sustain a continued increase in hair counts after 12 months. No systemic side effects were noted.

(Arch Dermatol 1987;123:1483-1487)